Laura Faivre

427 total citations
16 papers, 307 citations indexed

About

Laura Faivre is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Laura Faivre has authored 16 papers receiving a total of 307 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Laura Faivre's work include Lung Cancer Treatments and Mutations (6 papers), Lung Cancer Diagnosis and Treatment (4 papers) and Lung Cancer Research Studies (4 papers). Laura Faivre is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Lung Cancer Diagnosis and Treatment (4 papers) and Lung Cancer Research Studies (4 papers). Laura Faivre collaborates with scholars based in France, Switzerland and Italy. Laura Faivre's co-authors include Jean‐Charles Soria, Benjamin Besse, M.V. Bluthgen, Jean‐Pierre Pignon, David Planchard, Jordi Remón, Ludovic Lacroix, Caroline Even, Julien Adam and Stéphane Temam and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncotarget.

In The Last Decade

Laura Faivre

16 papers receiving 304 citations

Peers

Laura Faivre
Prabhsimranjot Singh United States
Alice Bernard‐Tessier France
Chukwuemeka Ikpeazu United States
Bojana Mitrovic Canada
Xiao Hu China
Hester C. van Wyk United Kingdom
Viorica Nagy Romania
Danilo Galizia Italy
Ruth Gabriela Herrera Gómez France
Prabhsimranjot Singh United States
Laura Faivre
Citations per year, relative to Laura Faivre Laura Faivre (= 1×) peers Prabhsimranjot Singh

Countries citing papers authored by Laura Faivre

Since Specialization
Citations

This map shows the geographic impact of Laura Faivre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Faivre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Faivre more than expected).

Fields of papers citing papers by Laura Faivre

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Faivre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Faivre. The network helps show where Laura Faivre may publish in the future.

Co-authorship network of co-authors of Laura Faivre

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Faivre. A scholar is included among the top collaborators of Laura Faivre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Faivre. Laura Faivre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Adam, Julien, Émilie Louvet, Tony Sourisseau, et al.. (2018). TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. ESMO Open. 3(1). e000257–e000257. 69 indexed citations
2.
3.
Lassau, Nathalie, Laura Faivre, Baya Benatsou, et al.. (2017). Study of Intrapatient Variability and Reproducibility of Quantitative Tumor Perfusion Parameters Evaluated With Dynamic Contrast-Enhanced Ultrasonography. Investigative Radiology. 52(3). 148–154. 23 indexed citations
4.
Mezquita, Laura, Mélinda Charrier, Laura Faivre, et al.. (2017). Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients. Lung Cancer. 112. 10–15. 4 indexed citations
5.
Bluthgen, M.V., Laura Faivre, Silvia Rosellini, et al.. (2017). Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study. Oncotarget. 9(2). 1906–1914. 11 indexed citations
6.
Bluthgen, M.V., Laura Faivre, Jean‐Pierre Pignon, et al.. (2017). LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. Lung Cancer. 112. 62–68. 88 indexed citations
7.
Carmel, Alexandra, Philippe Vielh, F. Lesaunier, et al.. (2017). The benefit of combining docetaxel to androgen deprivation therapy in localized and metastatic castration-sensitive prostate cancer as predicted by ERG status: An analysis of two GETUG phase III trials.. Journal of Clinical Oncology. 35(15_suppl). 5012–5012. 5 indexed citations
8.
Faivre, Laura, Jean‐Pierre Pignon, David Planchard, et al.. (2016). Abstract 2250: STK11 mutations in non-small cell lung cancer (NSCLC): descriptive analysis and prognostic significance. Cancer Research. 76(14_Supplement). 2250–2250. 1 indexed citations
9.
Vassal, Gilles, Laura Faivre, Birgit Geoerger, et al.. (2016). Crizotinib in children and adolescents with advanced ROS1, MET, or ALK-rearranged cancer: Results of the AcSé phase II trial.. Journal of Clinical Oncology. 34(15_suppl). 11509–11509. 10 indexed citations
10.
Guigay, J., Jérôme Fayette, Caroline Even, et al.. (2016). PACSA: Phase II study of pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC).. Journal of Clinical Oncology. 34(15_suppl). 6086–6086. 22 indexed citations
11.
Remón, Jordi, Laura Faivre, Francesco Facchinetti, et al.. (2016). Radiogenomics in 332 metastatic non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology. 34(15_suppl). 11563–11563. 3 indexed citations
12.
Hollebecque, Antoine, Rastislav Bahleda, Laura Faivre, et al.. (2015). Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumors.. Journal of Clinical Oncology. 33(15_suppl). 2599–2599. 1 indexed citations
13.
Moro‐Sibilot, Denis, Laura Faivre, Gérard Zalcman, et al.. (2015). Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial.. Journal of Clinical Oncology. 33(15_suppl). 8065–8065. 38 indexed citations
14.
Fizazi, Karim, Agnès Laplanche, F. Lesaunier, et al.. (2014). Docetaxel-estramustine in localized high-risk prostate cancer: Results of the French Genitourinary Tumor Group GETUG 12 phase III trial.. Journal of Clinical Oncology. 32(15_suppl). 5005–5005. 9 indexed citations
15.
16.
Vielh, Philippe, Agnès Laplanche, F. Lesaunier, et al.. (2014). A study of ERG, PTEN, and ki-67 in a phase III trial assessing docetaxel and estramustine in high-risk localized prostate cancer (GETUG 12).. Journal of Clinical Oncology. 32(15_suppl). 5063–5063. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Prabhsimranjot Singh Breakdown of academic impact, for papers by Alice Bernard‐Tessier Breakdown of academic impact, for papers by Chukwuemeka Ikpeazu Breakdown of academic impact, for papers by Bojana Mitrovic Breakdown of academic impact, for papers by Xiao Hu Breakdown of academic impact, for papers by Hester C. van Wyk Breakdown of academic impact, for papers by Viorica Nagy Breakdown of academic impact, for papers by Danilo Galizia Breakdown of academic impact, for papers by Ruth Gabriela Herrera Gómez
Rankless by CCL
2026